Acute phase proteins (APPs) are pivotal biomarkers in veterinary medicine, reflecting the intrinsic link between inflammation, infection and tissue injury in diverse animal species. Produced primarily ...

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...

Xervyteg demonstrated a 62% GI overall response rate at day 28, significantly exceeding historical controls, with durable responses and survival benefits over one year. The safety profile was ...